Scientific
Publications
- ASCPT 2023 | 3.23.2023
In Vitro, In Silico, and Clinical Investigations of BLU 5937 as Perpetrator of Drug Drug Interactions.
- AAAAI 2023 | 2.26.2023
Burden of Cough in Refractory Chronic Cough Population Enrolled in a Phase 2b Study of the P2X3 Antagonist BLU-5937.
- AAAAI 2023 | 2.26.2023
Cough Associated Diagnostic Journey of Participants in a Phase 2b Study in Refractory Chronic Cough.
- CHEST 2022 | 10.18.2022
Prior Specialist Consultations and Treatments in a Refractory Chronic Cough Population Enrolled In a Phase 2b Study of the P2X3 Antagonist BLU 5937.
- ERS 2022 | 9.4.2022
Efficacy in SOOTHE, A Phase 2b Trial of BLU-5937 In Refractory Chronic Cough, Was Not Dependent of Taste Disturbance Adverse Events.
- ERS 2022 | 9.4.2022
Characteristics of Participants with Refractory Chronic Cough Enrolled in A Phase 2b Trial of BLU-5937.
- ERS 2022 | 9.4.2022
Improvements In Awake Cough Frequency In Participants Treated With BLU-5937 In A Phase 2b Trial of BLU-5937 in Refractory Chronic Cough.
- ICS 2022 | 7.14.2022
Development of BLU-5937 for the Treatment of Refractory Chronic Cough.
- ATS 2022 | 5.17.2022
Safety And Efficacy of BLU-5937 In the Treatment of Refractory Chronic Cough from the Phase 2b SOOTHE Trial.
- ATS 2022 | 5.17.2022
Safety And Efficacy of BLU-5937 In the Treatment of Refractory Chronic Cough from the Phase 2b SOOTHE Trial.
- ATS 2022 | 5.16.2022
Responders Analyses in Objective 24H Cough Frequency in SOOTHE, A Phase 2b Trial of a Selective P2x3 Antagonist in Refractory Chronic Cough.
- ATS 2022 | 5.16.2022
Improvements in Cough Severity and Quality of Life in SOOTHE, A Phase 2b, Dose Finding Trial of BLU-5937 in Refractory Chronic Cough.
- ERS 2021 | 9.5.2021
Improvements in cough severity and cough related quality of life in a phase 2 trial with BLU 5937 in refractory chronic cough.
- ACC 2021 | 6.12.2021
Update on the Development of BLU 5937 for the Treatment of Refractory Chronic Cough.
- ATS 2021 | 5.20.2021
Design of SOOTHE, a Phase 2b Dose Finding Study with BLU 5937, a Selective P2X3 Antagonist, in Refractory Chronic Cough.
- ATS 2021 | 5.20.2021
Improvements in Cough Frequency over 24 Hours with BLU 5937, a Selective P2X3 Antagonist, in Patient Subgroups Defined by Baseline Awake Cough Frequencies.
- ATS 2021 | 5.20.2021
Baseline Characteristics and Burden of Disease in Populations Defined by Cough Frequency Tiers in RELIEF, a Phase 2 Study on the Efficacy and Safety of BLU 5937 in Refractory Chronic Cough.
- ICS 2021 | 1.22.2021
Results of RELIEF, a Phase 2a Study with BLU-5937 in Refractory Chronic Cough.
- ICS 2021 | 1.22.2021
BLU-5937, A Potent and Selective P2X3 Receptor Antagonist, Presents a Promising New Approach for the Treatment of Chronic Pruritus in Atopic Dermatitis Patients.
- ESDR 2019 | 9.21.2019
BLU-5937; A Potent and Selective P2X3 Antogonist, for the Treatment of Chronic Itch: Evidence from Preclinical Studies.
- ACC 2019 | 6.7.2019
BLU-5937: A Highly Selective P2X3 Homotrimeric Receptor Antagonist, Exhibits Excellent Pharmacokinetic and Safety Profile Including Improved Taste Safety Profile in Healthy Subjects.
- ATS 2019 | 5.21.2019
BLU-5937 a Highly Selective P2X3 Homotrimeric Receptor Antagonist with Improved Taste Safety Profile in Healthy Subjects.
- ELSEVIER | 3.20.2019
BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
- ICS 2018 | 6.27.2018
BLU-5937: A Selective P2X3 Antagonist With Potent Anti-Tussive Effect and No Taste Alteration.